Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (06901) of the EORTC Leukemia Cooperative Group
SourceAnnals of Hematology, 72, (1996), pp. 119-124
Article / Letter to editor
Display more detailsDisplay less details
Annals of Hematology
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.